Advertisement

Drugs & Aging

, Volume 27, Issue 2, pp 135–148 | Cite as

Drug Burden Index and Potentially Inappropriate Medications in Community-Dwelling Older People

The Impact of Home Medicines Review
  • Ronald L. Castelino
  • Sarah N. Hilmer
  • Beata V. Bajorek
  • Prasad Nishtala
  • Timothy F. Chen
Original Research Article

Abstract

Background

A significant problem in older people (aged ≥65 years) is the use of potentially inappropriate medications (PIMs), including those with sedative and anticholinergic properties. However, effective intervention strategies have yet to be identified. The Drug Burden Index (DBI) is an evidence-based tool that measures a person’s total exposure to medications with sedative and anticholinergic properties and has been shown to be independently associated with impairment in cognitive and physical function.

Objective

The main aim of the study was to investigate whether Home Medicines Review (HMR) services by pharmacists for community-dwelling older people would lead to an improvement in the use of medications, as measured by a decrease in the DBI score. The study also aimed to investigate the (i) distribution of DBI scores and PIMs among older people living in the community, and (ii) impact of pharmacists’ recommendations on DBI scores and PIMs.

Methods

A retrospective analysis of medication reviews was performed for 372 community-dwelling older people (aged ≥65 years) who received an HMR service from the pharmacist. The main outcome measure was the total DBI score at baseline and post-HMR. The data were also examined to determine the extent of PIM use (2003 Beers’ criteria), and the number and nature of pharmacists’ recommendations.

Results

Overall, medications contributing to the DBI (i.e. medications with sedative or anticholinergic properties) and PIMs were identified in 60.5% (n = 225) and 39.8% (n=148) of the patients, respectively. Following pharmacist recommendations during the HMR service, medications contributing to the DBI were identified in 51.6% (n = 192) of the patients. A statistically significant reduction in the sum total of DBI scores for all patients was observed following pharmacists’ recommendations during the HMR service (206.9 vs 157.3, p < 0.001). Pharmacists’ recommendations also led to a decrease in the use of PIMs, which were identified in 28.2% (n= 105) of the patients following the HMR service.

Conclusion

When the DBI is used for evaluation, pharmacists’ recommendations during HMR services, if acted upon, may effect changes in the prescribing of sedative and anticholinergic medications, thereby substantially reducing the patient’s drug burden. Future studies should focus on whether such a decrease may translate into functional improvements. The study also showed a positive influence of HMR services on the prescribing of PIMs.

Keywords

Amiodarone Medication Review Inappropriate Medication Anticholinergic Medication Sedative Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The author acknowledges the Australian Association of Consultant Pharmacy and the seven accredited pharmacists for providing access to de-identified medication reviews used in this study. Associate Professor Sarah Hilmer holds an international patent for the Drug Burden Index. The other authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother 2009; 43(6): 1096–106PubMedCrossRefGoogle Scholar
  2. 2.
    Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes: randomised controlled trial. Age Ageing 2006; 35(6): 586–91PubMedCrossRefGoogle Scholar
  3. 3.
    Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14(5): 447–50PubMedCrossRefGoogle Scholar
  4. 4.
    Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85(1): 86–8PubMedCrossRefGoogle Scholar
  5. 5.
    Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002; 18(3): 577–92PubMedCrossRefGoogle Scholar
  6. 6.
    Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents: UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151(9): 1825–32PubMedCrossRefGoogle Scholar
  7. 7.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531–6PubMedCrossRefGoogle Scholar
  8. 8.
    Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22): 2716–24PubMedCrossRefGoogle Scholar
  9. 9.
    Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286(2): 2823–9PubMedCrossRefGoogle Scholar
  10. 10.
    Page 2nd RL, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother 2006; 4(4): 297–305PubMedCrossRefGoogle Scholar
  11. 11.
    Barry PJ, O’Keefe N, O’Connor KA, et al. Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 2006; 31(6): 617–26PubMedCrossRefGoogle Scholar
  12. 12.
    Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool. Drugs Aging 2008; 25(9): 777–93PubMedCrossRefGoogle Scholar
  13. 13.
    Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167(8): 781–7PubMedCrossRefGoogle Scholar
  14. 14.
    Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008; 83(3): 422–9PubMedCrossRefGoogle Scholar
  15. 15.
    Gnjidic DCR, Le Couteur DG, Abernethy DR, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 2009; 68(1): 97–105PubMedCrossRefGoogle Scholar
  16. 16.
    Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med 2009; 122(12): 1142–9.e1-2PubMedCrossRefGoogle Scholar
  17. 17.
    Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332(9): 556–61PubMedCrossRefGoogle Scholar
  18. 18.
    Gray SL, Penninx BWJH, Blough DK, et al. Benzodiazepine use and physical performance in community-dwelling older women. J Am Geriatr Soc 2003; 51(11): 1563–70PubMedCrossRefGoogle Scholar
  19. 19.
    Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60(2): 198–203PubMedCrossRefGoogle Scholar
  20. 20.
    Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007; 81(2): 235–41PubMedCrossRefGoogle Scholar
  21. 21.
    Tinetti ME. Clinical practice: preventing falls in elderly persons. N Engl J Med 2003; 348(1): 42–9PubMedCrossRefGoogle Scholar
  22. 22.
    Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62Suppl. 2: 11–4PubMedGoogle Scholar
  23. 23.
    Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25(12): 1021–31PubMedCrossRefGoogle Scholar
  24. 24.
    van der Velde N, Stricker BHC, Pols HAP, et al. Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging 2007; 24(8): 691–9PubMedCrossRefGoogle Scholar
  25. 25.
    Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004; 389–14Google Scholar
  26. 26.
    Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9PubMedCrossRefGoogle Scholar
  27. 27.
    Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother 2004; 2: 3–13PubMedCrossRefGoogle Scholar
  28. 28.
    Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 2004; 164(3): 305–12PubMedCrossRefGoogle Scholar
  29. 29.
    Weekes LM, Mackson JM, Fitzgerald M, et al. National Prescribing Service: creating an implementation arm for national medicines policy. Br J Clin Pharmacol 2005; 59(1): 112–6PubMedCrossRefGoogle Scholar
  30. 30.
    Department of Health and Ageing, Australian Government. Medication Management Reviews [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-epc-dmmr-answers.htm#6 [Accessed 2009 Jun 17]
  31. 31.
    Nissen D, editor. Mosby’s drug consult. St Louis (MO): Mosby Inc., 2004Google Scholar
  32. 32.
    Duplay D, editor. Physicians’ desk reference. 58th ed. Mont-vale (NJ): Thomson PDR, 2004Google Scholar
  33. 33.
    Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298(3): 865–72PubMedGoogle Scholar
  34. 34.
    World Health Organization. International statistical classification of disease and related health problems. 10th rev. Geneva: World Health Organization, 1992 [online]. Available from URL: http://apps.who.int/classifications/apps/icd/icd10online/ [Accessed 2009 Dec 1]Google Scholar
  35. 35.
    WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. Oslo: World Health Organization, 2009 [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2009 Dec 1]Google Scholar
  36. 36.
    Nishtala PS, McLachlan AJ, Hannan PJ, et al. Drug Burden Index in aged care homes: impact of residential medication management reviews. Drugs Aging 2009; 26(8): 677–86PubMedCrossRefGoogle Scholar
  37. 37.
    Nishtala PS, McLachlan AJ, Bell JS, et al. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry 2008; 16(8): 621–32PubMedCrossRefGoogle Scholar
  38. 38.
    Pariente A, Dartigues J-F, Benichou J, et al. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008; 25(1): 61–70PubMedCrossRefGoogle Scholar
  39. 39.
    Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 1998; 64(6): 684–92PubMedCrossRefGoogle Scholar
  40. 40.
    Pomara N, Deptula D, Medel M, et al. Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. Psychopharmacol Bull 1989; 25(1): 144–8PubMedGoogle Scholar
  41. 41.
    Merchant RA, Li B, Yap KB. Use of drugs with anticholinergic effects and cognitive impairment in community-living older persons. Age Ageing 2008; 38: 105–8PubMedCrossRefGoogle Scholar
  42. 42.
    Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332(7539): 455–9PubMedCrossRefGoogle Scholar
  43. 43.
    Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14(11): 980–4PubMedCrossRefGoogle Scholar
  44. 44.
    Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15(1): 15–28PubMedCrossRefGoogle Scholar
  45. 45.
    Fick DM, Mion LC, Beers MH, et al. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health 2008; 31(1): 42–51PubMedCrossRefGoogle Scholar
  46. 46.
    Stuart B, Kamal-Bahl S, Briesacher B, et al. Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999. Am J Geriatr Pharmacother 2003; 1(2): 61–74PubMedCrossRefGoogle Scholar
  47. 47.
    Laroche M-L, Charmes J-P, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clinical Pharmacol 2007; 63(8): 725–31CrossRefGoogle Scholar
  48. 48.
    Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293(11): 1348–58PubMedCrossRefGoogle Scholar
  49. 49.
    Chin MH, Wang LC, Jin L, et al. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med 1999; 6(12): 1232–42PubMedCrossRefGoogle Scholar
  50. 50.
    Fick DM, Waller JL, Maclean JR, et al. Potentially inappropriate medication use in a Medicare managed care population: association with higher costs and utilization. J Manag Care Pharm 2001; 7 (Sep–Oct): 407–13Google Scholar
  51. 51.
    Hanlon JT, Fillenbaum GG, Kuchibhatla M, et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care 2002; 40(2): 166–76PubMedCrossRefGoogle Scholar
  52. 52.
    Fillenbaum GG, Hanlon JT, Landerman LR, et al. Impact of inappropriate drug use on health services utilization among representative older community-dwelling residents. Am J Geriatr Pharmacother 2004; 2(2): 92–101PubMedCrossRefGoogle Scholar
  53. 53.
    Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004; 58: 648–64PubMedCrossRefGoogle Scholar
  54. 54.
    Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacotherapy 2005; 39(1): 22–7CrossRefGoogle Scholar
  55. 55.
    Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001; 30: 205–11PubMedCrossRefGoogle Scholar
  56. 56.
    Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003; 16: 917–22Google Scholar
  57. 57.
    O’Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005; 39(9): 1423–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Ronald L. Castelino
    • 1
  • Sarah N. Hilmer
    • 2
    • 3
  • Beata V. Bajorek
    • 1
    • 2
  • Prasad Nishtala
    • 1
  • Timothy F. Chen
    • 1
  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia
  2. 2.Departments of Aged Care and Clinical PharmacologyRoyal North Shore Hospital, St LeonardsSydneyAustralia
  3. 3.Sydney Medical SchoolThe University of SydneySydneyAustralia

Personalised recommendations